



January 31, 2024

Company name: CHORI CO., LTD.
 Representative: Kazuo Sakihama, President, CEO & COO
 (Code: 8014, Tokyo (Prime Market))
 Inquiries: Yasutaka Kawamura
 Manager, Corporate Management Dept.
 (+81-3-5781-6201)

**Notice Regarding Revisions to the Forecast of Consolidated Financial Results
 for the Year Ending March 31, 2024**

CHORI CO., LTD. (the “Company”) hereby announces that, at its Board of Directors meeting held on January 31, 2024, it has decided to revise the forecast of consolidated financial results for the year ending March 31, 2024 (from April 1, 2023 to March 31, 2024), announced on April 28, 2023, in view of the recent performance trends.

1. Revisions to the forecast of consolidated financial results for the year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

	Net sales	Operating profit	Ordinary profit	Net profit attributable to owners of parent	Net profit per share
Previous forecast (A) (Announced on Apr. 28, 2023)	Millions of yen 340,000	Millions of yen 14,200	Millions of yen 14,000	Millions of yen 9,400	Yen 382.00
Revised forecast (B)	310,000	14,200	14,000	9,400	382.00
Change (B-A)	-30,000	0	0	0	
Change (%)	-8.8	0.0	0.0	0.0	
[Reference] Previous fiscal year results (Fiscal year ended Mar. 31, 2023)	329,389	12,656	12,437	8,124	330.16

2. Reasons for the revisions

As the Company announced today, for the nine months ended December 31, 2023, net sales decreased from the same period of the previous fiscal year, primarily due to decreased sales resulting from an overall decline in demand and a slump in market conditions in the Chemicals business. Meanwhile, profits increased owing to improved profitability as well as significant expansion of the Fibers, Textiles and Garments business, driven by the recovery of the Japanese apparel market. Based on these results, we have revised the forecast of net sales we announced on April 28, 2023. However, the profit forecast remains unchanged as solid progress has been made.

(Note) The forecast above is based on information available as of the date of this publication. Actual results may differ due to various factors going forward.